Methylergonovine (Methergine) is contraindicated in patients with asthma due to significant risk of bronchospasm and should be avoided.
Primary Recommendation
Methylergonovine should not be used in asthmatic patients. The European Society of Cardiology explicitly states that "methylergonovine is contraindicated because of the risk (>10%) of vasoconstriction and hypertension" 1, and while this guideline addresses cardiovascular concerns, the vasoconstrictor properties extend to bronchial smooth muscle, posing serious risk to asthmatic patients.
Evidence Supporting Avoidance
Drug Label Information
The FDA-approved drug label for Methergine does not list asthma as a specific contraindication in the precautions section 2, which represents a critical gap in labeling. However, the drug's mechanism as an ergot alkaloid with potent smooth muscle effects creates inherent risk for bronchospasm.
Clinical Evidence
Recent observational data demonstrates that carboprost (another uterotonic with bronchoconstrictive properties) is used 32% less frequently in asthmatic patients (adjusted risk ratio 0.68,95% CI 0.62-0.74), suggesting clinicians actively avoid agents with bronchospasm risk in this population 3. While this study focused on carboprost, the principle applies to all uterotonics with smooth muscle effects.
Safer Alternatives for Postpartum Hemorrhage
When managing postpartum hemorrhage in asthmatic patients, use this hierarchy:
First-line: Oxytocin - Safe and effective with no bronchospasm risk 4
- Administer as slow IV infusion (<2 U/min) to avoid hypotension 1
Second-line: Misoprostol - No respiratory contraindications
- Particularly useful in resource-limited settings 4
Avoid entirely:
- Methylergonovine (ergot alkaloid with smooth muscle effects)
- Carboprost (prostaglandin F2α - known bronchospasm risk) 3
Critical Clinical Considerations
If methylergonovine is inadvertently administered to an asthmatic patient:
- Monitor closely for bronchospasm development
- Have short-acting beta-agonists (albuterol) immediately available
- Consider prophylactic bronchodilator administration
- The risk of status asthmaticus requiring intervention is real, as demonstrated with similar vasoactive agents 3
The cardiovascular safety profile of methylergonovine shows minimal risk for acute coronary syndrome (risk difference 1.44 per 100,000 patients) 5, but this does not address respiratory safety in asthmatics.
Bottom Line
Choose oxytocin as the primary uterotonic in all asthmatic patients. The combination of ergot alkaloid smooth muscle effects, clinical practice patterns showing avoidance of similar agents, and explicit guideline contraindications for vasoconstrictor effects makes methylergonovine an inappropriate choice when safer, equally effective alternatives exist 1, 3, 4.